There is converging evidence from neuropsychological studies that growth hormone (GH) is associated with cognitive function. The aim of the current study was to review the existing neuropsychological literature for studies in which cognitive assessment had been conducted in patients with GH deficiency (GHD), and where change in cognitive function had been assessed following treatment with GH. Studies that have investigated relationships between GH and cognitive function and those that have developed methodological and statistical approaches that could be useful in future GH studies were identified. In this review, GH levels were found to be associated with cognitive function. Untreated individuals with GHD showed reliable impairment in memory and attentional functions when compared with matched controls. Appropriately designed prospective studies also indicated that cognitive function improved with GH treatment. It was concluded that individuals with GHD do show cognitive impairment and that this is ameliorated to some extent by GH treatment. It is now important to establish the clinical importance of these findings, and further work is required to understand better the nature, magnitude and meaning of GH-related cognitive impairments and improvements.

1.
Baum HBA, Katznelson L, Sherman JC, Biller BMK, Hayden DL, Schoenfeld DA, Cannistraro KE, Klibanski A: Effects of physiological growth hormone (GH) therapy on cognition and quality of life in patients with adult-onset GH deficiency. J Clin Endocrinol Metab 1998;83:3184–3189.
2.
Bulow B, Hagmar L, Orbaek P, Osterberg K, Erfurth EM: High incidence of mental disorders, reduced mental well-being and cognitive function in hypopituitary women with GH deficiency treated for pituitary disease. Clin Endocrinol 2002;56:183–193.
3.
Degerblad M, Almkvist O, Grunditz R, Hall K, Kaijser L, Knutsson E, Ringertz H, Thoren M: Physical and psychological capabilities during substitution therapy with recombinant growth hormone in adults with growth hormone deficiency. Acta Endocrinol 1990;123:185–193.
4.
Deijen JB, de Boer H, Blok GJ, van der Veen EA: Cognitive impairments and mood disturbances in growth hormone deficient men. Psychoneuroendocrinology 1996;21:313–322.
5.
Deijen JB, de Boer H, van der Veen EA: Cognitive changes during growth hormone replacement in adult men. Psychoneuroendocrinology 1998;23:45–55.
6.
Golgeli A, Tanriverdi F, Suer C, Gokce C, Ozesmi C, Bayram F, Kelestimur F: Utility of P300 auditory event related potential latency in detecting cognitive dysfunction in growth hormone (GH) deficient patients with Sheehan’s syndrome and effects of GH replacement therapy. Eur J Endocrinol 2004;150:153–159.
7.
Lijffijt M, van Dam PS, Kenemans JL, Koppeschaar HPF, de Vries WR, Drent ML, Wittenberg A, Kemner C: Somatotropic-axis deficiency affects brain substrates of selective attention in childhood-onset growth hormone deficient patients. Neurosci Lett 2003;353:123–126.
8.
Peace KA, Orme SM, Padayatty SJ, Godfrey HPD, Belchetz PE: Cognitive dysfunction in patients with pituitary tumour who have been treated with transfrontal or transsphenoidal surgery or medication. Clin Endocrinol 1998;49:391–396.
9.
Van Dam PS, de Winter CF, de Vries R, van der Grond J, Drent ML, Lijffijt M, Kenemans JL, Aleman A, de Haan EH, Koppeschaar HP: Childhood-onset growth hormone deficiency, cognitive function and brain N-acetylaspartate. Psychoneuroendocrinology 2005;30:357–363.
10.
Almqvist O, Thoren M, Saaf M, Eriksson O: Effects of growth hormone substitution on mental performance in adults with growth hormone deficiency: a pilot study. Psychoneuroendocrinology 1986;11:347–352.
11.
Arwert LI, Deijen JB, Muller M, Dren ML: Long-term growth hormone treatment preserves GH-inducted memory and mood improvements: a 10-year follow-up study in GH-deficient adult men. Horm Behav 2005;47:343–349.
12.
Oertel H, Schneider HJ, Stalla GK, Holsboer F, Zihl J: The effect of growth hormone substitution on cognitive performance in adult patients with hypopituitarism. Psychoneuroendocrinology 2004;29:839–850.
13.
Pavel ME, Lohman T, Hahn EG, Hoffman M: Impact of growth hormone on central nervous system activity, vigilance and tiredness after short term therapy in growth hormone-deficient adults. Horm Metab Res 2003;35:114–119.
14.
Sartorio A, Molinari E, Riva G, Conti A, Morabito F, Faglia G: Growth hormone treatment in adults with childhood onset growth hormone deficiency: effects on psychological capabilities. Horm Res 1995;44:6–11.
15.
Stouthart PJHM, Deijen JB, Roffel M, Delemarre-van de Waal HA: Quality of life of growth hormone (GH) deficient young adults during discontinuation and restart of GH therapy. Psychoneuroendocrinology 2003;28:612–626.
16.
Collie A, Maruff P, Darby DG, McStephen M: The effects of practice on the cognitive test performance of neurologically normal individuals assessed at brief test-retest intervals. J Int Neuropsychol Soc 2003;9:419–428.
17.
Monson JP, Cook DM: Growth Hormone Deficiency in Adults: A Pocket Guide to Clinical Management. Pennsylvania, Apothecom Associates LLC. 2003.
18.
Cohen J: Statistical Power Analysis for the Behavioural Sciences, ed 2. New York, Academic Press, 1988.
19.
Lezak MD: Neuropsychological Assessment, ed 3. New York, Oxford University Press, 1995.
20.
Darby D, Walsh K: Clinical Neuropsychology, ed 5. London, Churchill Livingston. 2005.
21.
Collie A, Makdissi M, Maruff P, Bennell K, McCrory P: Cognitive function in the days following concussion: a comparison of symptomatic vs asymptomatic athletes. Neurology 2005 (in press).
22.
Maruff P, Collie A, Darby D, Weaver-Cargin J, Masters C: Subtle cognitive decline over 12 months in mild cognitive impairment. Dement Geriatr Cogn Disord 2004;18:342–348.
23.
Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT: A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Neurology 1998;50:136–145.
24.
Growth Hormone Research Society: Consensus for the diagnosis and treatment of adults with growth hormone deficiency; summary statement of the Growth Hormone Research Society workshop on adult growth hormone deficiency. J Clin Endocr Metab 1998;83:379–381.
25.
Maruff P: Validity of the CogState computerized cognitive test battery: sensitivity to mild traumatic brain injury, mild cognitive impairment, schizophrenia and AIDS dementia complex. Clin Neuropsychol 2005, in press.
26.
Collie A, Maruff P, Makdissi M, McCrory P, McStephen M, Darby D: CogSport: reliability and correlation with conventional cognitive tests used in postconcussion medical evaluations. Clin J Sports Med 2003;13:28–32.
27.
Silbert B, Maruff P, Evered L, Scott D, Kalpokas M, Martin K, Lewis MS, Myles PS: Detection of cognitive decline after coronary surgery: a comparison of computerized and conventional tests. Br J Anaesth 2004;92:814–820.
28.
Mollica C, Maruff P, Vance A: Development of a statistical approach to classifying treatment response in individual children with ADHD. Hum Psychopharmacol 2004;19:445–456.
29.
Falleti MG, Maruff P, Collie A, Darby DG, McStephen M: Qualitative similarities in cognitive impairment associated with 24 h of sustained wakefulness and a blood alcohol concentration of 0.05%. J Sleep Res 2003;12:265–274.
30.
Maruff P, Falleti M, Darby D, McStephen M: Fatigue related impairment in the speed, accuracy and variability of psychomotor performance: comparison with blood alcohol levels. J Sleep Res 2005;14:21–27.
31.
Harris G, McCrory P, Collie A: The effects of altitude of cognitive performance. Presented at Australian Conference on Science and Medicine in Sports, Alice Springs, Australia, October 2004.
32.
Darby D, Maruff P, Collie A, McStephen M: Repeated administration of a cognitive test battery in mild cognitive impairment. Neurology 2002;59:1042–1046.
33.
Makdissi M, Collie A, Maruff P, Darby DG, Bush A, McCrory P, Bennell K: Computerised cognitive assessment of concussed Australian Rules footballers. Br J Sports Med 2001;35:354–360.
34.
Burman P, Deijen JB: Quality of life and cognitive function in patients with pituitary insufficiency. Psychother Psychosom 2001;67:154–167.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.